Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Two Doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years of Age and Older, Living With HIV.

NCT05005156 is registered in ClinicalTrials.gov with Fundación Huésped as lead sponsor.

NCT NCT05005156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05005156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Two Doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years of Age and Older, Living With HIV.
Lead sponsor
Fundación Huésped
Phase
Phase 2
Overall status
Completed
Start date
June 24, 2021
Completion date
January 13, 2023
Enrollment
155 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid19